Vantage logo

What’s in a p value?

Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…

Vantage logo

Clearside’s future clouds over

After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.

Vantage logo

Daybreak clouds over for Lundbeck

A treatment-resistant schizophrenia drug would have been a blockbuster – but Lundbeck’s high risk, high-reward strategy has not paid off.